Q4 Earnings Estimate for BLFS Issued By Northland Capmk

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Equities research analysts at Northland Capmk issued their Q4 2025 earnings per share estimates for shares of BioLife Solutions in a research note issued on Wednesday, January 8th. Northland Capmk analyst C. Byrnes anticipates that the medical equipment provider will post earnings of $0.00 per share for the quarter. The consensus estimate for BioLife Solutions' current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions' FY2026 earnings at $0.10 EPS.

A number of other analysts have also recently commented on BLFS. KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. HC Wainwright dropped their target price on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Wednesday. Benchmark reissued a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, TD Cowen lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, BioLife Solutions presently has an average rating of "Moderate Buy" and a consensus price target of $29.43.

BioLife Solutions Stock Performance

Shares of BLFS stock traded down $1.08 during trading hours on Friday, hitting $26.61. 207,142 shares of the company were exchanged, compared to its average volume of 215,540. BioLife Solutions has a 52-week low of $14.50 and a 52-week high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a fifty day simple moving average of $25.99 and a 200 day simple moving average of $24.29. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -25.10 and a beta of 1.92.

Insider Buying and Selling at BioLife Solutions

In other news, CEO Greef Roderick De sold 46,896 shares of the business's stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the sale, the chief executive officer now owns 414,958 shares in the company, valued at approximately $9,722,465.94. The trade was a 10.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Troy Wichterman sold 987 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 113,129 shares of company stock valued at $2,576,818. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently made changes to their positions in the business. Mark Sheptoff Financial Planning LLC purchased a new position in BioLife Solutions during the third quarter valued at $28,000. Quest Partners LLC bought a new position in shares of BioLife Solutions during the third quarter valued at $57,000. GAMMA Investing LLC raised its position in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 748 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in BioLife Solutions in the 2nd quarter worth about $122,000. Finally, Arizona State Retirement System purchased a new stake in BioLife Solutions during the 2nd quarter valued at about $217,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.